The effect of β-adrenergic receptor antagonism in cardiac sympathetic neuronal remodeling in patients with heart failure

International Journal of Cardiology

Volumn 106, Issue 1, 2006, Pages 29-34

  Chizzola, Paulo Roberto ^a,b   Gonçalves De Freitas, Humberto Felício ^a   Marinho, Norma Vasconcelos Saldanha ^a   Mansur, José Alfredo ^a   Meneghetti, José Cláudio ^a   Bocchi, Edimar Alcides ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE   (Brazil)

Author keywords

adrenergic receptor antagonists; 123I metaiodobenzylguanidine; Cardiac sympathetic neuronal remodeling; Carvedilol; Heart failure

Indexed keywords

(3 IODOBENZYL)GUANIDINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; IODINE 123; NORADRENALIN; PLACEBO;

ADRENERGIC SYSTEM; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONGESTIVE CARDIOMYOPATHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HEART; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; IMAGE ANALYSIS; MALE; MEDIASTINUM; NORADRENALIN BRAIN LEVEL; NORADRENALIN UPTAKE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; THORAX SCINTISCANNING; TITRIMETRY;

3-IODOBENZYLGUANIDINE; ADRENERGIC BETA-ANTAGONISTS; ADULT; CARBAZOLES; CARDIOMYOPATHY, DILATED; DOUBLE-BLIND METHOD; FEMALE; HEART FAILURE, CONGESTIVE; HEART VENTRICLES; HUMANS; MALE; MIDDLE AGED; NOREPINEPHRINE; PROPANOLAMINES; RADIOPHARMACEUTICALS; SYMPATHETIC NERVOUS SYSTEM; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 28444465519     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2004.12.050     Document Type: Article

References (40)

1. M. Packer for the US Carvedilol Heart Failure Study Group The effect of carvedilol on morbidity and mortality in patients with chronic heart failure N Engl J Med 334 1996 1349 1355
2. P. DasGupta, P. Broadhurst, and A. Lahiri The effects of intravenous carvedilol, a new multiple action vasodilatory β-blocker, in congestive heart failure J Cardiovasc Pharmacol 18 Suppl.4 1991 S12 S16
3. G.Z. Feuerstein, A. Bril, and R.R. Ruffolo Jr. Protective effects of carvedilol in the myocardium Am J Cardiol 80 11A 1997 41L 45L
4. M. Schäfers, O. Schober, and H. Lerch Cardiac sympathetic neurotransmission scintigraphy Eur J Nucl Med 25 1998 435 441
5. J.C. Sisson, D.M. Wieland, and P. Sherman Metaiodobenzylguanidine as an index of the adrenergic nervous system integrity and function J Nucl Med 28 1987 1620 1624
6. J.V. Glowniak, F.E. Turner, and L.L. Gray Iodine-123 metaiodobenzylguanidine imaging of the heart in idiopathic congestive cardiomyopathy and cardiac transplants J Nucl Med 30 1989 1182 1191
7. J. Schofer, R. Spielmann, and A. Schuchert Iodine-123 meta-iodobenzylguanidine scintigraphy: a noninvasive method to demonstrate myocardial adrenergic disintegrity in patients with idiopathic dilated cardiomyopathy J Am Coll Cardiol 12 1988 1252 1258
8. P. Merlet, H. Valette, and J.L. Dubois Randé Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure J Nucl Med 33 1992 471 477
9. P. Merlet, J.L. Dubois Randé, and S. Adnot Myocardial beta-adrenergic desensitization and neuronal norepinephrine uptake function in idiopathic dilated cardiomyopathy J Cardiovasc Pharmacol 19 1992 10 16
10. R. Standke, G. Hör, and F.D. Maul Fully automated sectorial equilibrium radionuclide ventriculography Eur J Nucl Med 8 1983 77 83
11. C.L. Davies, and S.C. Molyneux Routine determination of plasma catecholamines using reversed-phase, ion-pair high-performance liquid chromatography with electrochemical detection J Cromatogr 231 1982 41 51
12. B.J. Winer, D.R. Brown, and K.M. Michels Statistical principles in experimental design 3rd ed. 1991 MacGraw-Hill New York
13. H. Krum, J.D. Sackner Bernstein, and R.L. Goldsmith Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure Circulation 92 1995 1499 1506
14. M. Metra, M. Nardi, R. Giubbini, and L. Dei Cas Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy J Am Coll Cardiol 24 1994 1678 1687
15. M. Packer, W.S. Colucci, and J.D. Sackner Bernstein Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE trial. Prospective randomized evaluation of carvedilol on symptoms and exercise Circulation 94 1996 2793 2799
16. S.L. Osle, E.M. Gilbert, and D.G. Renlund Carvedilol improves left ventricular function and symptoms in chronic heart failure. A double-blind randomized study J Am Coll Cardiol 25 1995 1225 1231
17. Australia-New Zealand Heart Failure Research Collaborative Group Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease Circulation 92 1995 212 218
18. E.A. Bocchi, F. Bacal, and G. Bellotti Efeitos do carvedilol (bloqueador β1, β2, α1) na insuficiência cardíaca refratária Arq Bras Cardiol 71 1998 169 173
19. M.R. Bristow for the MOCHA investigators Carvedilol produces dose-related improvement in left ventricular function and survival in subjects with chronic heart failure Circulation 94 1996 2807 2816
20. R.N. Doughty, G.A. Whalley, and G. Gamble Left ventricular remodeling with carvedilol in patients with congestive heart due to ischemic heart disease J Am Coll Cardiol 29 1997 1060 1066
21. R.A. Quaif, E.M. Gilbert, and P.E. Christian Effects of carvedilol on systolic and diastolic left ventricular performance in idiopathic dilated cardiomyopathy or ischemic cardiomyopathy Am J Cardiol 78 1996 779 784
22. M. Fujimura, Y. Yasumura, and Y. Ishida Improvement in left ventricular function in response to carvedilol is accompanied by attenuation of neurohumoral activation in patients with dilated cardiomyopathy J Card Fail 6 2000 3 10
23. C. Maunoury, P. Acar, and D. Sidi Use of 1231-MIBG scintigraphy to assess the impact of carvediol on cardiac adrenergic neuronal function in childhood dilated cardiomyopathy Eur J Nucl Med Imaging 30 2003 1651 1656
24. M.C. Gerson, L.L. Craft, N. McGuire, D.P. Suresh, W.T. Abraham, and L.E. Wagoner Carvedilol improves left ventricular function in heart failure patients with idiopathic dilated cardiomyopathy and a wide range of sympathetic nervous system function as measured by iodine 123 metaiodobenzylguanidine J Nucl Cardiol 9 2002 608 615
25. J.Y. Choi, K.H. Lee, K.P. Hong, B.T. Kim, J.D. Seo, and W.R. Lee Iodine-123 MIBG imaging before treatment of heart failure with carvedilol to predict improvement of left ventricular function and exercise capacity J Nucl Cardiol 8 2001 4 9
26. 123I-metaiodobenzylguanidine uptake J Nucl Med 42 2001 49 54
27. 123I-MIBG scintigraphic study J Nucl Med 41 2000 845 851
28. G.A. Somsen, B. van Vlies, and P.A. de Milliano Increased myocardial [123I]-metaiodobenzylguanidine uptake after enalapril treatment in patients with chronic heart failure Heart 76 1996 218 222
29. Takeishi, H. Atsumi, S. Fujiwara, K. Takahashi, and H. Tomoike ACE inhibition reduces cardiac iodine-123-MIBG release in heart failure J Nucl Med 38 1997 1085 1089
30. T. Toyama, H. Hoshizaki, R. Seki, N. Isobe, H. Adachi, and S. Naito Efficacy of carvedilol treatment on cardiac function and cardiac sympathetic nerve activity in patients with dilated cardiomyopathy: comparison with metoprolol therapy J Nucl Med 44 2003 1604 1611
31. 123I-MIBG in the failing human heart J Nucl Med 40 1999 224 231
32. K. Swedberg, C.H. Bergh, K. Dickstein, J. McNey, M. Steinberg Moxonidine Investigators The effects of moxonidine, a novel imidazoline, on plasma norepinephrine in patients with congestive heart failure J Am C Cardiol 35 2000 398 404
33. D.J. Van Veldhuisen, and P. Poole-Wilson The underreporting of results and possible mechanisms of "negative" drug trials in patients with chronic heart failure Int J Cardiol 80 2001 19 27
34. C.G. Jones, and J.G.F. Cleland Meeting report-the LIDO, HOPE, MOXCON and WASH studies Eur J Heart Fail 1 1999 425 431
35. E.B. Henderson, J.K. Kahn, and J.R. Corbett Abnormal I-123 metaiodobenzylguanidine myocardial washout and distribution may reflect myocardial adrenergic derangement in patients with congestive cardiomyopathy Circulation 78 1988 1192 1199
36. G.A. Somsen, B.M. Szabó, and D.J. van Veldhuisen Comparison between iodine 123 metaiodobenzylguanidine scintigraphy and heart rate variability for the assessment of cardiac sympathetic activity in mild to moderate heart failure Am Heart J 134 1997 456 458
37. D.L. Mann, R.L. Kent, B. Parsons, and G. Cooper IV Adrenergic effects on the biology of the adult mammalian cardiocyte Circulation 85 1992 790 804
38. F. Qing, S.U. Rahman, and M.J. Hayes Effect of long-term β2-agonist dosing on human cardiac β-adrenoceptor expression in vivo: comparison with changes in lung and mononuclear leukocyte β-receptors J Nucl Cardiol 4 1997 532 538
39. P. Merlet, C. Benvenuti, and D. Moyse Prognostic value of MIBG imaging in idiopathic dilated cardiomyopathy J Nucl Med 40 1999 917 923
40. A. Cohen Solal, Y. Esanu, and D. Logeart Cardiac metaiodobenzylguanidine uptake in patients with moderate chronic heart failure: relationship with peak oxygen uptake and prognosis J Am Coll Cardiol 33 1999 759 766